KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Regeneron Pharmaceuticals (REGN) Interest & Investment Income (2016 - 2017)

Regeneron Pharmaceuticals (REGN) has 9 years of Interest & Investment Income data on record, last reported at -$6.0 million in Q4 2017.

  • For Q4 2017, Interest & Investment Income rose 61.18% year-over-year to -$6.0 million; the TTM value through Dec 2017 reached -$25.1 million, down 58.17%, while the annual FY2017 figure was -$25.1 million, 249.12% down from the prior year.
  • Interest & Investment Income reached -$6.0 million in Q4 2017 per REGN's latest filing, up from -$6.2 million in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $2.8 million in Q2 2016 and bottomed at -$18.2 million in Q4 2015.
  • Average Interest & Investment Income over 5 years is -$2.9 million, with a median of -$158000.0 recorded in 2015.
  • Peak YoY movement for Interest & Investment Income: surged 105.48% in 2014, then crashed 1566.67% in 2016.
  • A 5-year view of Interest & Investment Income shows it stood at -$2.3 million in 2013, then soared by 174.24% to $1.7 million in 2014, then tumbled by 1186.11% to -$18.2 million in 2015, then grew by 14.65% to -$15.5 million in 2016, then skyrocketed by 61.18% to -$6.0 million in 2017.
  • Per Business Quant database, its latest 3 readings for Interest & Investment Income were -$6.0 million in Q4 2017, -$6.2 million in Q3 2017, and -$5.4 million in Q2 2017.